2D'Amato RJ, Loughnan MS, Flynn E, et al. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA, 1994, 91 : 4082-4085.
3Junquera F, Saperas E, de Torres I,et al. Increased expression of angiogenic factors in human colonic angiodysplasia. Am J Gastroenterol, 1999,94: 1070-1076.
4Ozawa CR, Banff A, Glazer NL, et al. Microenvironmental VEGF concentration, not total dose, determines a threshold between normal and aberrant angiogenesis. J Clin Invest,2004, 113:516-527.
5Wolkenstein P, Latarjet J, Roujeau JC, et al. Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis. Lancet, 1998, 352: 1586-1589.
6Bauditz J, Schachschal G, Wedel S, et al. Thalidomide for treatment of severe intestinal bleeding. Gut, 2004, 53: 609-612.
7Chen TL, Vogelsang GB, Petty BG, et al. Plasma pharmacokinetics and urinary excretion of thalidomide after oral dosing in healthy male volunteers. Drug Metab Dispos, 1989,17: 402-405.
8Bowers M, McNulty O, Mayne E. Octreotide in the treatment of gastrointestinal bleeding caused by angiodysplasia in two patients with yon Willebrand's disease. Br J Haematol, 2000, 108: 524-527.
9Orlandi M, Inauen W. Chronic gastrointestinal bleeding. Ther Umsch, 2006, 63:327-332.
10Chao CC, Ng Jao YT, Mo LR. Capsule endoscopy for gastrointestinal bleeding with an obscure etiology. J Formos Med Assoe, 2005,104:659-665.
8Lewis BS,Rey JF,Seisman EG.Capsule endoscopy:Result of the 2005 International Consensus Conference introduction[J].Endoscopy,2005,37:1038.
9Fujimori S,Gudis K,Takahashi Y.Distribution of small intestinal mucosal injuries as a result of NSAID administration[J].Eur J Clin Invest,2010,40(6):504.
10Carpi F.Magnetic capsule endoscopy:the future is around the corner[J].Expert Rev Med Devices,2010,7(2):161.
